Third quarter Shareholder Letter provides updates on Benson Hill’s strategic transformation, sustainability approach, and ...

Company reports third sequential quarter of record growth, contributing to a record total of $199.0 million in revenue for the first nine-months ...

Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data ...

(1) The percentage change for the following items were excluded as they were determined to be not meaningful due to a loss or negative position in one or both periods. QTD: net loss, diluted loss per ...

Year-to-date cash generated from operating activities increased by $97 million to $212 million, enabling continued net debt1 reduction and a return of $61.7 million in capital to shareholders1 ...

Reported positive YTD 2024 Adjusted EBITDA of $1.4 millionCompany expects Q4 2024 Net Revenue in the range of $37 million - $43 millionZYNRELEF® (bupivacaine and meloxicam) extended-release solution ...

CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy," or the "Company") a leading lithium-ion battery manufacturer ...